US Stock Market Closed

Dashboard

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity
Analyst Opinion

B

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

CEO

Christian Martin Itin

Employees

-

Industry

-

Sector

-

Headquarters

London

Exchange

NASDAQ

Summary Stats

Market Cap

228M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 8 analysts

High

$50.00

Average

$27.75

Low

$13.00

Ratings calculated by 10 analysts

Buy

9

Hold

1

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Not Available

Actual

-$0.47 -

Consensus

-

Report Date

Year Ago

-0.47

Year Ago Change %

Up 0%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites